July 7 (Reuters) - Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering ...
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...
24/7 Wall St. on MSN
Jim Cramer calls biotech “the hottest group in the market” as he predicts “deals are going to be flooding the market”
Quick ReadJim Cramer predicts a biotech takeover flood, with Lilly posting $19.8B Q1 revenue and Gilead closing a $7.8B ...
Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
1mon
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...
Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
Explore advancements in biotechnology, from gene editing's ethical dilemmas to synthetic biology's commercial potential and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results